-
Bayer’s Corporate Reports About Their YAZ / Yasmin Settlement Program Show Progress Continues To Be Made, Albeit At A Slow Pace
First Lawsuits In The YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral Drug Injury Litigation Were Filed In 2009, With Thousands Of Cases Still Pending (Posted by Tom Lamb at…
-
Xarelto, Savaysa, Pradaxa, And Eliquis: Safety Secondary To Ease Of Use Is “A Major Wrong Turn” Says Drug Watchdog Group
This New Generation Of Oral Anticoagulants Has Bleeding-Related Adverse Reactions Including Gastrointestinal And Intracranial Bleeds (Posted by Tom Lamb at DrugInjuryWatch.com) The ISMP QuarterWatch published on September 23, 2015 includes an examination…
-
Still No Approved Reversal Agents Or Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
None Available To Help Patients Who Undergo Emergency Surgery Or When There Is Life-Threatening Uncontrolled Bleeding (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: On October 16, 2015 the FDA granted accelerated approval…
-
Potential Link Between MS Drug Gilenya And Cancers, Neoplasms, Or Tumors According To Health Canada
This September 2015 Drug Safety Alert Is Based Primarily On Reports Of Skin Cancer And Lymphoma Blood Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) Health Canada recently conducted a review of safety…
